Financial disclosures released ahead of confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the health department, show that he plans to divest stock holdings, including stakes in CRISPR Therapeutics (CRSP) and privately-held Dragonfly Therapeutics, reported STAT. Shares of CRISPR are up 6% to $43.98 in afternoon trading.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics call volume above normal and directionally bullish
- Cathie Wood’s ARK Investment bought 147K shares of Crispr Therapeutics today
- Cathie Wood’s ARK Invest Boosts CRISPR Therapeutics (NASDAQ:CRSP) Stake
- Cathie Wood’s ARK Investment bought 133K shares of Crispr Therapeutics today
- Crispr Therapeutics highlights strategic priorities, anticipated milestones